ReachMD

Be part of the knowledge.™

Pathology and Lab Medicine

72

LikeLikedUnlike

Episodes 16-30 of 67

MET Inhibition in Metastatic NSCLC “In the Spotlight”
CME/CE
MET Inhibition in Metastatic NSCLC “In the Spotlight”
- Paul Paik, MD
  Peer
- D. Ross Camidge, MD, PhD
  Peer
- Keith Kerr, BSc, MB ChB
  Peer
0.25 credits
New Treatments for Residual Excessive Daytime Sleepiness in Obstructive Sleep Apnea
MinuteCE®
New Treatments for Residual Excessive Daytime Sleepiness in Obstructive Sleep Apnea
- Christina Finch, MD
  Peer
1.00 program credits
MinuteCE®
Triple-Negative Breast Cancer (TNBC): Choosing the Right ADC for the Right Patient
- Sara A. Hurvitz, MD, FACP
  Peer
- Sara M. Tolaney MD, MPH
  Peer
1.00 credits 9 episodes
ADC Targets: Does Positivity Really Matter?
MinuteCE®
ADC Targets: Does Positivity Really Matter?
- Sara M. Tolaney MD, MPH
  Peer
1.00 program credits
Which TNBC Patients Are Eligible for ADCs?
MinuteCE®
Which TNBC Patients Are Eligible for ADCs?
- Sara A. Hurvitz, MD, FACP
  Peer
1.00 program credits
How Do We Apply Evidence Supporting TROP2 Directed ADCs to the Metastatic TNBC Treatment Paradigm?
MinuteCE®
How Do We Apply Evidence Supporting TROP2 Directed ADCs to the Metastatic TNBC Treatment Paradigm?
- Sara M. Tolaney MD, MPH
  Peer
1.00 program credits
What Is the Evidence for ADCs in HR-/HER2-Low Metastatic Breast Cancer?
MinuteCE®
What Is the Evidence for ADCs in HR-/HER2-Low Metastatic Breast Cancer?
- Sara M. Tolaney MD, MPH
  Peer
1.00 program credits
Metastatic TNBC: Utilizing Biology and Health Disparities to Inform Shared Decision Making
MinuteCE®
Metastatic TNBC: Utilizing Biology and Health Disparities to Inform Shared Decision Making
- Sara A. Hurvitz, MD, FACP
  Peer
1.00 program credits
What Factors Impact Use of ADCs in Special Patient Populations with Metastatic TNBC?
MinuteCE®
What Factors Impact Use of ADCs in Special Patient Populations with Metastatic TNBC?
- Sara A. Hurvitz, MD, FACP
  Peer
1.00 program credits
How Are We Addressing Unanswered Questions Around ADCs in Metastatic TNBC?
MinuteCE®
How Are We Addressing Unanswered Questions Around ADCs in Metastatic TNBC?
- Sara A. Hurvitz, MD, FACP
  Peer
- Sara M. Tolaney MD, MPH
  Peer
1.00 program credits
What Do Patients/Caregivers Need To Know About ADCs in Metastatic TNBC?
MinuteCE®
What Do Patients/Caregivers Need To Know About ADCs in Metastatic TNBC?
- Sara M. Tolaney MD, MPH
  Peer
1.00 program credits
What Is the Future of ADCs in Metastatic TNBC?
MinuteCE®
What Is the Future of ADCs in Metastatic TNBC?
- Sara A. Hurvitz, MD, FACP
  Peer
- Sara M. Tolaney MD, MPH
  Peer
1.00 program credits
MinuteCE®
Expanding ADCs Across Metastatic Breast Cancer: Disrupting Dx & Tx Silos
- Erica L. Mayer, MD, MPH
  Peer
- Sarah Sammons, MD
  Peer
1.00 credits 9 episodes
What Are the Clinical and Therapeutic Implications of the Evolving HER2 Testing Landscape?
MinuteCE®
What Are the Clinical and Therapeutic Implications of the Evolving HER2 Testing Landscape?
- Sarah Sammons, MD
  Peer
1.00 program credits
What Are the Data for HER2-Targeted ADCs in HR+/HER2-Low Metastatic Breast Cancer?
MinuteCE®
What Are the Data for HER2-Targeted ADCs in HR+/HER2-Low Metastatic Breast Cancer?
- Erica L. Mayer, MD, MPH
  Peer
1.00 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended